Lori J. Wirth, MD, on Advanced Thyroid Carcinoma: Evolving Systemic Therapy Options

March 30, 2021 By The ASCO Post Staff

Lori J. Wirth, MD, of Massachusetts General Hospital Cancer Center, discusses the common molecular alterations across thyroid cancer subtypes; targeted treatments for BRAF V600E–mutant, NTRK–fusion positive, and RET–altered disease; and optimal therapies for patients with multiple types of thyroid cancer.

Related Content